TY - JOUR
T1 - Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs)
T2 - A systematic review
AU - Pezzilli, Raffaele
AU - Partelli, Stefano
AU - Cannizzaro, Renato
AU - Pagano, Nico
AU - Crippa, Stefano
AU - Pagnanelli, Michele
AU - Falconi, Massimo
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background We systematically evaluate the current evidence regarding Ki-67 as a prognostic factor in pancreatic neuroendocrine neoplasms to evaluate the differences of this marker in primary tumors and in distant metastases as well as the values of Ki-67 obtained by fine needle aspiration and by histology. Methods The literature search was carried out using the MEDLINE/PubMed database, and only papers published in the last 10 years were selected. Results The pancreatic tissue suitable for Ki-67 evaluation was obtained from surgical specimens in the majority of the studies. There was a concordance of 83% between preoperative and postoperative Ki-67 evaluation. Pooling the data of the studies which compared the Ki-67 values obtained in both cytological and surgical specimens, we found that they were not related. The assessment of Ki-67 was manual in the majority of the papers considered for this review. In order to eliminate manual counting, several imaging methods have been developed but none of them are routinely used at present. Twenty-two studies also explored the role of Ki-67 utilized as a prognostic marker for pancreatic neuroendocrine neoplasms and the majority of them showed that Ki-67 is a good prognostic marker of disease progression. Three studies explored the Ki-67 value in metastatic sites and one study demonstrated that, in metachronous and synchronous liver metastases, there was no significant variation in the index of proliferation. Conclusions Ki-67 is a reliable prognostic marker for pancreatic neuroendocrine neoplasms.
AB - Background We systematically evaluate the current evidence regarding Ki-67 as a prognostic factor in pancreatic neuroendocrine neoplasms to evaluate the differences of this marker in primary tumors and in distant metastases as well as the values of Ki-67 obtained by fine needle aspiration and by histology. Methods The literature search was carried out using the MEDLINE/PubMed database, and only papers published in the last 10 years were selected. Results The pancreatic tissue suitable for Ki-67 evaluation was obtained from surgical specimens in the majority of the studies. There was a concordance of 83% between preoperative and postoperative Ki-67 evaluation. Pooling the data of the studies which compared the Ki-67 values obtained in both cytological and surgical specimens, we found that they were not related. The assessment of Ki-67 was manual in the majority of the papers considered for this review. In order to eliminate manual counting, several imaging methods have been developed but none of them are routinely used at present. Twenty-two studies also explored the role of Ki-67 utilized as a prognostic marker for pancreatic neuroendocrine neoplasms and the majority of them showed that Ki-67 is a good prognostic marker of disease progression. Three studies explored the Ki-67 value in metastatic sites and one study demonstrated that, in metachronous and synchronous liver metastases, there was no significant variation in the index of proliferation. Conclusions Ki-67 is a reliable prognostic marker for pancreatic neuroendocrine neoplasms.
KW - Immune system disease
KW - Ki-67
KW - Pancreatic neuroendocrine neoplasms
KW - Prognosis
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=84960122343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960122343&partnerID=8YFLogxK
U2 - 10.1016/j.advms.2015.10.001
DO - 10.1016/j.advms.2015.10.001
M3 - Article
VL - 61
SP - 147
EP - 153
JO - Advances in Medical Sciences
JF - Advances in Medical Sciences
SN - 1896-1126
IS - 1
ER -